Arbutus Biopharma

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company primarily dedicated to discovering, developing, and commercializing a broad portfolio of assets with diverse modes of action to provide treatment options for patients with chronic hepatitis B virus (HBV) infection. The company is advancing multiple candidate products with various mechanisms of action that can inhibit viral replication, reduce surface antigens, and reawaken the immune system. Arbutus has an extensive HBV asset pipeline aimed at reducing surface antigens, suppressing viral replication, and enhancing the immune system, including: RNAi therapeutics, oral PD-L1 inhibitors, oral HBV RNA stabilizers, and other preclinical drug assets for coronaviruses.